Icatibant, an antagonist of the bradykinin B2 receptor, was a approved for the treatment of acute attacks of hereditary angioedema in the EU in 2008. This paper presents the case of a 65-year-old woman affected by frequent acute attacks of hereditary angiodema who benefitted from a change of therapy to icatibant, following years of treatment with Cl-inhibitor.
Switch to icatibant in a patient affected by hereditary angioedema with high disease activity: A case report
FIRINU, DAVIDE;MANCONI, PAOLO EMILIO;DEL GIACCO, STEFANO
2012-01-01
Abstract
Icatibant, an antagonist of the bradykinin B2 receptor, was a approved for the treatment of acute attacks of hereditary angioedema in the EU in 2008. This paper presents the case of a 65-year-old woman affected by frequent acute attacks of hereditary angiodema who benefitted from a change of therapy to icatibant, following years of treatment with Cl-inhibitor.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Firinu D et al IJIP 2012001.pdf
accesso aperto
Tipologia:
versione editoriale (VoR)
Dimensione
343.53 kB
Formato
Adobe PDF
|
343.53 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
